Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The results for the primary endpoint are shown in Table 13 for both the per-protocol and intent-to-treat populations and indicate similarity of insulin glargine to NPH in the progression of diabetic retinopathy as assessed by this outcome
*Reduction in A1C is dependent upon a number of factors, such as baseline A1C and background therapy
One thing many guides skip: have a flat, clean, well-lit surface ready
Lifestyle changes become critical after discontinuation
However, patients with severe obesity, poorly controlled type 2 diabetes, or those who still need aggressive weight reduction often do better from staying on injectable therapy because it tends to be more powerful at higher doses
US$ 28.26
US$ 25.22
US$ 23.24
US$ 26.63
US$ 20.05
